• Torin2 Workflows for mTOR Inhibitor Cancer Research

  2026-08-19

  Build more informative Torin2 experiments by pairing selective mTOR pathway inhibition with viability, migration, and apoptosis assays. This workflow also incorporates a recent RNA Pol II discovery to distinguish active death signaling from nonspecific transcriptional collapse.

• SGC-CBP30: From Enhancers to Assay Design

  2026-08-19

  SGC-CBP30 is a selective CREBBP/EP300 bromodomain inhibitor for connecting coactivator biology with actionable assay design. This article translates lung adenocarcinoma findings into rigorous epigenetics research workflows while separating established evidence from testable mechanisms.

• Bradykinin BA5201: Practical Research Workflow

  2026-08-18

  Bradykinin BA5201 provides an identified research peptide for controlled studies of endothelial vasodilation, vascular permeability, smooth muscle responses, pain, and inflammation signaling. Use it for scientific research with freshly prepared, assay-specific solutions; it is not a diagnostic or medical product, and model-specific validation remains necessary.

• Tamoxifen Research Workflows for CreER and Cancer

  2026-08-18

  Tamoxifen is both a selective estrogen receptor modulator for cancer biology and a practical trigger for CreER-mediated gene knockout. This workflow-oriented guide shows how to control formulation, distinguish intended recombination from estrogen-related confounding, and translate mitochondrial iron findings into stronger assays.

• Verteporfin A8327: Reliable Cell Assays

  2026-08-17

  Learn how Verteporfin (SKU A8327), also known as CL 318952, can be incorporated into controlled viability, cytotoxicity, apoptosis, and autophagy experiments. This scenario-based guide emphasizes light and vehicle controls, documented concentration ranges, orthogonal readouts, and practical product-selection criteria.

• Poly (I:C) Workflows for Innate Immune Assays

  2026-08-17

  Build reproducible interferon and dendritic-cell activation assays with Poly (I:C), while separating extracellular TLR3 stimulation from cytosolic dsRNA-sensing experiments. A cardiomyocyte-focused workflow translates recent JPH2 findings into practical controls for immune-stress studies, including hPSC-derived models.

• TMEM16F Lipid Scrambling in Ferroptosis and Immunity

  2026-08-16

  Yang et al. identify TMEM16F-mediated phospholipid scrambling as a late-stage suppressor of ferroptosis that protects the plasma membrane after lipid peroxide accumulation. Disabling this process converts membrane injury into lytic, immunogenic death and improves the response of tumors to PD-1 blockade, providing a mechanistic link between membrane biophysics and tumor immunity.

• Idoxuridine Workflows for Viral DNA Research

  2026-08-15

  Idoxuridine provides a practical nucleoside-analog workflow for examining viral DNA synthesis, replication timing, and herpes simplex virus research endpoints. This guide combines solvent and stability controls with time-of-addition experiments, orthogonal readouts, and a cautious cross-domain lesson from human DRG electrophysiology research.

• Sunitinib Workflows for RCC Resistance Studies

  2026-08-14

  Build reproducible Sunitinib assays that connect RTK blockade with angiogenesis, apoptosis, cell-cycle control, and metabolic drug resistance. A practical workflow shows how to compare sensitive and resistant renal cell carcinoma models and test glycolysis-focused combination strategies.

• Structural Basis of P/Q-Type Cav2.1 Toxin Sensitivity

  2026-08-14

  The 2024 Cell Research study combines electrophysiology and near-atomic-resolution cryo-EM to explain why P-type and Q-type Cav2.1 channels respond differently to ω-agatoxin IVA. Its structures place the toxin at the extracellular voltage-sensing domain IV and connect alternative splicing in the S3–S4IV loop with altered toxin sensitivity, providing a mechanistic framework for selective Cav2.1 channel modulation.

• CF10–EdU Synergy Drives Telomere Attrition in CRC

  2026-08-13

  The reference study shows that the fluoropyrimidine polymer CF10 synergizes strongly with 5-ethynyl-2′-deoxyuridine (EdU), unlike the additive interaction observed with EdU plus 5-fluorouracil. The combination increases EdU incorporation, DNA double-strand breaks, telomere signal loss, cell-cycle disruption, and mitotic catastrophe in colorectal cancer models, providing a mechanistic framework for studying drug-induced telomere attrition.

• GS-441524 Workflows for Prodrug Conversion

  2026-08-13

  Build more informative antiviral and pharmacokinetic studies with GS-441524, from DMSO stock preparation to LC–MS/MS tracking across biological matrices. The workflow distinguishes parent-compound activity from prodrug conversion, helping researchers connect cell responses with exposure and metabolite formation.

• COX-2 in Venom-Induced Muscle Ischemia

  2026-08-12

  A Microvascular Research study shows that COX-2 has a time-dependent role after Bothrops asper venom injury: it helps preserve vascular integrity during acute ischemia, whereas early inhibition later enhances angiogenic and matrix-remodeling signals. The findings refine how selective COX-2 inhibition should be interpreted in muscle injury and revascularization models.

• LY2228820: Selective p38 MAP Kinase Inhibitor

  2026-08-12

  LY2228820 is a selective ATP-competitive p38 MAP kinase inhibitor that targets p38α and p38β with nanomolar biochemical potency. It supports mechanistic studies of p38 MAPK signaling, cytokine release, tumor biology, and bortezomib-associated cytotoxicity.

• L. gasseri, NR1I3, and E-Cadherin in Colitis

  2026-08-11

  This study identifies a mechanistic pathway in which Lactobacillus gasseri ATCC33323 protects against DSS-induced colitis by regulating NR1I3-associated CDH1 transcription and preserving E-cadherin-dependent epithelial barrier function. Its combination of probiotic intervention, intestinal E-cadherin loss-of-function models, transcriptional analysis, and in vitro validation provides a stronger causal framework than probiotic efficacy measurements alone.

16403 records 1/1094 page Next 12345 下5页 Last page